China's aids vaccine with independent intellectual property rights begins Phase I clinical trials

the first group of volunteers were vaccinated at the ConcordHospital in Beijing on the 1st
, the DNA-Tiantanpox Miao compound AIDS vaccine jointly developed by the China Center forDiseasePrevention and Control and the Beijing Institute of Biological ProductsThis means that China's independent intellectual property rights of aids vaccine began to carry out Phase I clinical trialsAccording to experts from the ChinaDiseasePrevention and Control Center
thethe AIDS vaccine includes two components of the DNA vaccine and the replication of the recombinant pox virus vaccine,has China's independent intellectual property rightsThe vaccine was originally selected from The most widely prevalent HIV strain in China, CRF-07
,including four genes, gag, pol, env and nefThe vector of the vaccine chose the Temple of Heaven's pox seed virus, because the pox seed virus has been widely used in China's smallpox vaccine, the safety has been used by hundreds of millions of people fully verified This recombinant AIDS vaccine has passed the strict identification of relevant parties, quality qualified, the National Food Drug administration approved by the Administration of Drugs and Supervision for Phase I clinical trials If the vaccine Phase I clinical trial is successful, the researchers will also conduct long-term research in Phase II and Phase III The vaccine development has received funding from the National 863 Program and related EU projects According to reports, the international AIDS vaccine research has been more than 20 years, although the cost of more than 100 clinical trials of such a vaccine, but there is no effective vaccine, two completed Phase III clinical trials have failed Up to now, the internationally declared failure of AIDS vaccines are protein vaccine or non-replicated vector vaccine, belong to the dead vaccine With the international epidemic of AIDS vaccine design concept and technical route is very different, China's researchers this clinical trial is a copy of the pox virus vector, belongs to the live vaccine, can cause a strong immune response in animals Animal experiments show that the vaccine can induce a good body fluid and cellular immune response in mice and monkeys, and can have a protective effect on monkey infection /
monkey immunodeficiency virus Experts , the current international AIDS vaccine industry is showing a trend from non-replicated vectors to replication vectors China's ongoing AIDS vaccine clinical trials are at the forefront of this trend
, is currently the only ongoing replication of the carrier AIDS vaccine clinical trials